Mitochondrial metabolic remodeling predicts therapeutic response to PegIFN-α in chronic hepatitis B
Frontiers in Cellular and Infection Microbiology · 2026
DOI: 10.3389/fcimb.2025.1719456 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2026. Verfasst von Yingying Zhang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, The Fourth Affiliated Hospital of Soochow University, Suzhou Dushu Lake Hospital, Suzhou, Jiangsu, China. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Interferon-alpha, Mitochondria, Antiviral Agents. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Chronic hepatitis B (CHB) remains a global health challenge, with current therapies achieving low rates of functional cure (FC). Reliable biomarkers are urgently needed to guide individualized treatment. This study characterized the immune–metabolic profiles of CHB patients receiving pegylated interferon-α (PegIFN-α) or nucleos(t)ide analogues (NAs), focusing on mitochondrial function as a novel predictor of therapeutic response.
Methods
A total of 93 CHB patients and 32 healthy controls were recruited from three centers. Peripheral blood leukocyte subsets and mitochondrial parameters, including mitochondrial mass (MM) and the percentage of cells with low mitochondrial membrane potential (MMPlow%), were assessed by flow cytometry. Multivariate logistic regression and receiver operating characteristic (ROC) analyses were used to identify independent predictors and evaluate biomarker performance for FC.
Results
Untreated CHB patients showed marked mitochondrial depletion across immune subsets. NA therapy normalized mitochondrial parameters without improving FC rates, whereas PegIFN-α therapy selectively remodeled CD4+ T cell metabolism and promoted monocyte differentiation. Improved mitochondrial efficiency in CD8+ T cells and elevated monocyte counts were closely associated with HBsAg clearance. Lymphocyte MMPlow% showed the strongest individual predictive value, while an integrated immune–metabolic model further enhanced accuracy for FC prediction.
Conclusion
Immune–metabolic remodeling underlies PegIFN-α–induced functional cure in CHB. Mitochondrial profiling provides a promising framework for precision stratification and immune-based therapeutic optimization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, The Fourth Affiliated Hospital of Soochow University, Suzhou Dushu Lake Hospital, Suzhou, Jiangsu, China.
- Center of Clinical Laboratory and Translational Medicine, The Fourth Affiliated Hospital of Soochow University, Suzhou Dushu Lake Hospital, Suzhou, Jiangsu, China.
- Medical College of Soochow University, Suzhou, Jiangsu, China.
- Center of Clinical Laboratory, The Fifth People's Hospital of Suzhou, Suzhou, Jiangsu, China.
Zitieren
APA
Zhang, Y., Han, X., Xu, C., Song, Y., Zhu, J., Zhou, R., Chen, Y., Liu, M., Xu, J., Wu, X., Han, Q., & Chen, Z. (2026). Mitochondrial metabolic remodeling predicts therapeutic response to PegIFN-α in chronic hepatitis B. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2025.1719456
Vancouver
Zhang Y, Han X, Xu C, Song Y, Zhu J, Zhou R, et al. Mitochondrial metabolic remodeling predicts therapeutic response to PegIFN-α in chronic hepatitis B. Frontiers in Cellular and Infection Microbiology. 2026. doi:10.3389/fcimb.2025.1719456
BibTeX
@article{Zhang2026,
author = {Zhang, Yingying and Han, Xiu and Xu, Chengyu and Song, Yahui and Zhu, Jinghan and Zhou, Ruoran and Chen, Yiling and Liu, Mingming and Xu, Junchi and Wu, Xiangwei and Han, Qingzhen and Chen, Zutao},
title = {Mitochondrial metabolic remodeling predicts therapeutic response to PegIFN-α in chronic hepatitis B},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2026},
doi = {10.3389/fcimb.2025.1719456}
}
EUVIMED